Tyvaso Inhaled denied as not medically necessary by Cigna?

Cigna's specific coverage criteria for tyvaso inhaled are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denies Tyvaso (Inhaled Treprostinil) on Medical-Necessity Grounds

Cigna, like most commercial insurers, applies a structured medical-necessity review before approving Tyvaso (inhaled treprostinil) for pulmonary arterial hypertension (PAH) or pulmonary hypertension associated with interstitial lung disease (PH-ILD). A medical-necessity denial typically means the reviewer concluded the submitted documentation did not demonstrate that the patient's clinical profile meets the criteria outlined in Cigna's coverage policy and the FDA-approved labeling.

This denial is routinely appealable. Inhaled treprostinil has an established FDA-approved indication, and clinical guidelines from organizations such as the American College of Chest Physicians and the Pulmonary Hypertension Association support its use in appropriate patients. A well-documented appeal can succeed.

## Your Federal Appeal Rights

If your plan is governed by the ACA or ERISA, you have the following protections:

• Internal appeal: Submit a first-level appeal to Cigna, typically within 180 days of the denial notice. Cigna must respond within standard timeframes (or faster for urgent situations).
• External review (ACA §2719 / ERISA §503): If the internal appeal fails, request an independent external review through an accredited Independent Review Organization (IRO). You generally have approximately four months from the date of the internal appeal denial to file. The IRO's decision is binding on the insurer.
• Expedited review: If your condition is urgent, request expedited internal and external review simultaneously — insurers must respond within days.

## Documentation to Gather

1. Confirmed diagnosis: Records establishing PAH or PH-ILD, including right heart catheterization results and imaging reports. 2. Functional classification: Chart notes documenting WHO/NYHA functional class as assessed by the treating pulmonologist or cardiologist. 3. Prior-treatment history: A complete list of previously tried PAH therapies — names, dates started, dates stopped, and reasons for discontinuation or inadequate response. 4. Clinical severity: Objective markers from the chart such as six-minute walk distance, echocardiographic data, and exercise tolerance — without specific numeric claims from your end, simply cite what the chart states. 5. Prescriber letter of medical necessity: The specialist should explain why Tyvaso is medically necessary for this specific patient, referencing the FDA label and applicable guideline organization recommendations.

## Criteria-Mapping Strategy

Obtain the exact current version of Cigna's coverage policy for inhaled treprostinil (search Cigna's public policy library). List every stated requirement. Then, for each requirement, identify the precise chart entry, test result, or clinical note that satisfies it. Present this as a one-to-one mapping in your appeal letter. Do the same for the FDA-approved prescribing information — confirm your prescriber documents that the patient meets the labeled indication as written.

This structured approach demonstrates to the reviewer that every coverage criterion is met, which is the most common pathway to reversal on medical-necessity grounds.